This session will review the risks and benefits of CT screening and the organizations that have endorsed screening in the past one to two years since the landmark NLST publication. It will cover risk modeling to help clinicians determine whom should potentially be screened for lung cancer. The most promising biomarkers will be reviewed to determine their future potential for incorporation into screening for lung cancer. At the conclusion of this activity, the learner will be able to do the following: 1. Identify the risk versus benefits of CT screening for lung cancer and the current recommendation of major organizations on whom to screen. 2. Elucidate the major contributors of high risk for lung cancer that may lead to a potentially useful risk model. 3. Enumerate the most promising biomarkers of lung cancer risk that may be clinically useful in the near future.